• Affiliate Professor, Global Health
Phone Number: 
Select from the following:

Dr. Eve Lackritz is the Zika Task Force Lead at the World Health Organization in Geneva. Dr. Lackritz joined WHO after serving as Deputy Director of the Global Alliance to Prevent Prematurity and Stillbirth (GAPPS) in Seattle, where she implemented a global research initiative with the Bill & Melinda Gates Foundation to investigate causes of preterm birth and stillbirth, and strategies for monitoring safety of maternal immunizations in LMICs. Dr. Lackritz served the prior 23 years at CDC in Atlanta. She served as Branch Chief of CDC’s Maternal and Infant Health Branch, and with CDC’s global HIV/AIDS programs, including implementation and evaluation of the first national antiretroviral treatment programs in Africa, clinical trials to prevent mother-to-child HIV transmission, and identification of new routes of HHV-8 transmission in Africa, the etiologic agent of Kaposi’s sarcoma. She also served in CDC’s Malaria Branch, studying malaria, anemia, and child survival in sub-Saharan Africa. Dr. Lackritz received her Doctor of Medicine at the Ohio State University, residency in pediatrics at Case Western Reserve/University Hospitals of Cleveland, and is board certified in pediatrics.

Country Affiliations 
  • French
Health Topics 
  • Child Mortality
  • Epidemiology
  • Health Interventions
  • Maternal Child Health (incl. Reproductive Health)
  • Maternal Mortality
  • Viruses
DGH Centers, Programs and Initiatives and Affiliated Organizations 

Lackritz EM, Wilson CB, Guttmacher AE, et al. A solution pathway for preterm birth: accelerating a priority research agenda. Lancet Global Health 2013; 1(6):328-30. doi:10.1016/S2214-109X(13)70120-7.

Callaghan WM, Rasmussen SA, MacDorman MF, Qin C, Lackritz EM. The contribution of preterm birth to infant mortality rates in the United States. Pediatrics 2006; 118:1566-73.

Hladik H, Dollard SC, Mermin J, LaMonte A, Downing R, Amin R, Banage F, Nzaro E, Kataaha P, Dondero TJ, Pellett PE, Lackritz EM. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006, 355:1331-8.

Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugyenyi P, Mermin J, Samb B, Lackritz E. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients’ response, survival, and drug resistance. Lancet 2002; 360:34-40.

Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VS, Janssen RS, Notari EP,Lewis WF, Petersen LR. Estimated risk transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med 1995;333:1721-5.